NewEdge Wealth’s Mustang Bio MBIO Stock Holding History

NewEdge Wealth’s Portfolio MBIO Stock Details MBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-20	Closed	-$5.5K	–	654
2023 Q1	$5.5K	Buy	+20	New	+$8.2K	﹤0.01%	608

Other funds holding MBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KOC

Koss-Olinger Consulting Gainesville, Florida $1.19B AUM 15.91% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

NewEdge Wealth's MBIO Position: Q2 2023 in Review

NewEdge Wealth sold out of Mustang Bio (MBIO) in Q2 2023, closing a stake of 20 shares — an estimated $5.5K sold.

NewEdge Wealth first reported a position in MBIO in Q1 2023 and held it in 1 quarter. The position peaked at $5.5K in Q1 2023. 27 funds tracked by Wall St. Rank hold MBIO as of Q2 2023.

NewEdge Wealth reported no remaining Mustang Bio position as of Q2 2023 after selling out during the quarter.
NewEdge Wealth sold 20 Mustang Bio shares in Q2 2023, an estimated $5.5K.
NewEdge Wealth first reported a position in Mustang Bio in Q1 2023 and held it in 1 quarter.
NewEdge Wealth's Mustang Bio position peaked at $5.5K in Q1 2023.
27 funds tracked by Wall St. Rank held Mustang Bio as of Q2 2023.

Based on NewEdge Wealth's 13F filing for Q2 2023, filed 9 Aug 2023.